NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PRTG

Portage Biotech Inc

Jul 01 • 10:50AM ET

5.71

Dollar change +0.19
Percentage change 3.44	%

Healthcare • Biotechnology • United Kingdom • NASD

Peers: VRTX GILD AMGN REGN ROG BMRN BIIB BNTX EXEL INCY

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-65.69	Insider Own	75.46%	Shs Outstand	1.12M	Perf Week	6.13%
Market Cap	6.40M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.28M	Perf Month	-28.98%
Enterprise Value	3.97M	PEG	-	EPS next Q	-	Inst Own	2.76%	Short Float	3.13%	Perf Quarter	-38.27%
Income	-67.28M	P/S	-	EPS this Y	-	Inst Trans	2.66%	Short Ratio	0.01	Perf Half Y	2.15%
Sales	0.00M	P/B	4.56	EPS next Y	-	ROA	-136.43%	Short Interest	0.01M	Perf YTD	10.44%
Book/sh	1.25	P/C	3.64	EPS next 5Y	-	ROE	-194.84%	52W High	23.01 -75.18%	Perf Year	26.33%
Cash/sh	1.57	P/FCF	-	EPS past 3/5Y	-42.38% -48.08%	ROIC	-4812.45%	52W Low	2.10 172.16%	Perf 3Y	-95.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.82% 10.93%	Perf 5Y	-97.39%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	48.91%	Oper. Margin	-	ATR (14)	0.74	Perf 10Y	-97.14%
Dividend Ex-Date	-	Quick Ratio	3.08	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.12	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.08	EPS Q/Q	78.19%	SMA20	-12.39%	Beta	0.58	Target Price	140.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-27.58%	Rel Volume	0.03	Prev Close	5.52
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	-3.23%	Avg Volume	903.40K	Price	5.71
IPO	Jan 21, 1999	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	6,818	Change	3.44%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-22	Resumed	Oppenheimer	Outperform	$26
Mar-07-22	Initiated	H.C. Wainwright	Buy	$32
Sep-21-21	Initiated	Oppenheimer	Outperform	$30
Sep-02-21	Initiated	B. Riley Securities	Buy	$40
Aug-19-21	Initiated	Cantor Fitzgerald	Overweight	$35

Jun-25-25 07:00AM	Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire) +13.57%
Jun-09-25 06:00AM	Portage Biotech and Compedica Stock-for-Stock Exchange (GlobeNewswire) -9.63%
Apr-28-25 06:00AM	Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 (GlobeNewswire) +27.46%
Mar-27-25 04:15PM	Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 (GlobeNewswire) +103.82%
Mar-12-25 08:00AM	Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial (GlobeNewswire)
04:15PM	Loading…
Feb-12-25 04:15PM	Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements (GlobeNewswire)
Jan-30-25 04:30PM	Portage Biotech Announces Completion of $2.15 Million Private Financing (GlobeNewswire)
Jan-06-25 05:00AM	Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company (GlobeNewswire)
Dec-17-24 07:00AM	Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd (GlobeNewswire) +178.15%
Dec-12-24 04:15PM	Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter (GlobeNewswire) -21.47%
Nov-26-24 04:05PM	Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 (GlobeNewswire) -13.55%
Aug-27-24 08:00AM	Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update (GlobeNewswire)
Aug-15-24 07:00AM	Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update (GlobeNewswire) +62.79%
Aug-13-24 07:00AM	Portage Biotech Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -18.10%
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:05AM	Loading…
Apr-15-24 07:05AM	Immuno-oncology company Portage Biotech to evaluate strategic alternatives (Pharmaceutical Business Review) -25.27%
Apr-12-24 10:33AM	Portage Biotech previews possible closure as it halts programs, hunts for strategic options (FierceBiotech.com) -9.00%
08:01AM	Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives (GlobeNewswire)
Mar-26-24 08:01AM	Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares (GlobeNewswire) +9.73%
Feb-28-24 05:10PM	Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update (GlobeNewswire) -15.71%
Jan-04-24 08:00AM	Portage Biotech Reports Business and Strategic Update (GlobeNewswire)
Nov-28-23 04:01PM	Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update (GlobeNewswire) +8.46%
Nov-06-23 08:01AM	Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-29-23 08:00AM	Portage Biotech Announces $6.0 Million Registered Direct Offering (GlobeNewswire) -7.52%
Sep-20-23 08:00AM	Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:00AM	Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors (GlobeNewswire) +26.81%
Aug-30-23 08:00AM	Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update (GlobeNewswire) -13.36%
Jul-31-23 04:05PM	Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update (GlobeNewswire) +7.69% -7.76%
Jun-26-23 08:00AM	Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors (GlobeNewswire)
Jun-05-23 08:00AM	Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Jun-01-23 08:00AM	Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference (GlobeNewswire) +5.17%
Apr-26-23 05:00PM	Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Portage Biotech to Present at Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire) -5.69%
Mar-01-23 08:00AM	Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022 (GlobeNewswire)
Feb-27-23 04:05PM	Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer (GlobeNewswire) +6.94%
Feb-15-23 08:00AM	Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Nov-29-22 04:43PM	Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022 (GlobeNewswire)
Nov-10-22 09:00AM	Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Nov-08-22 08:00AM	Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck (GlobeNewswire)
Sep-14-22 08:39AM	Portage Biotech Provides Research and Development Update (GlobeNewswire)
Sep-08-22 08:00AM	Portage Biotech to Present at Upcoming Investor Conferences (GlobeNewswire) -7.31%
Aug-29-22 08:00AM	Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022 (GlobeNewswire)
Aug-18-22 08:00AM	Portage Biotech Announces Leadership Updates (GlobeNewswire)
Aug-01-22 09:10AM	UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022 (GlobeNewswire)
08:00AM	Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022 (GlobeNewswire)
Jul-20-22 09:00AM	Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform (GlobeNewswire) +6.13%
Jul-06-22 04:05PM	Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway (GlobeNewswire)
Jun-06-22 08:00AM	Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study (GlobeNewswire) -8.47%
Apr-25-22 08:00AM	Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity (GlobeNewswire) +8.33%
Apr-13-22 10:00AM	Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting (GlobeNewswire) +8.95%
Mar-31-22 08:00AM	Portage Biotech Provides Update on Clinical-Stage and Development Programs (GlobeNewswire)
Mar-09-22 09:00AM	Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting (GlobeNewswire)
Feb-24-22 05:43PM	Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year (GlobeNewswire) +13.79%
Feb-15-22 08:00AM	Portage Biotech Announces New Appointments to its Management Team and Board of Directors (GlobeNewswire) +11.90%
Jan-05-22 08:00AM	Portage Biotech Announces Participation in January 2022 Investor Conferences (GlobeNewswire)
Nov-23-21 08:00AM	Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year (GlobeNewswire)
Nov-22-21 04:53PM	Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire) -7.06%
Nov-15-21 08:00AM	Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics INT230-6 (PORT-1) at November Scientific Conferences (GlobeNewswire)
Nov-10-21 08:00AM	Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology Treatment (GlobeNewswire) -6.53%
Oct-26-21 10:13AM	2 Strong Buy Stocks Oppenheimer Predicts Will Surge at Least 50% (TipRanks)
Sep-10-21 08:00AM	Portage Biotech Announces Participation in September 2021 Investor Conferences (GlobeNewswire)
Aug-30-21 08:00AM	Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year (GlobeNewswire)
Aug-12-21 08:00AM	Portage Biotech Issues Letter to Shareholders (GlobeNewswire)
Aug-05-21 08:00AM	Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC) (GlobeNewswire) +14.29%
Jul-28-21 08:00AM	Portage Biotech Announces Results for Fiscal Year Ended March 31, 2021 (GlobeNewswire)
Jun-29-21 09:00AM	Portage Biotech Added to Russell 2000(R) Index (Newsfile) -5.21%
Jun-24-21 09:00AM	Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary Shares (Newsfile) -25.43%
08:56AM	Thursdays Pre-Market: Heres What You Need to Know Before the Market Opens (TipRanks)
Jun-23-21 04:10PM	Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares (Newsfile)
Jun-02-21 08:30AM	Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics' IT-01 Study of INT230-6 (PORT-1) at ASCO 2021 Annual Meeting (Newsfile)
Apr-16-21 09:00AM	Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange (Newsfile) -7.06%
Apr-08-21 09:00AM	Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors (Newsfile)
Mar-25-21 09:00AM	Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics (Newsfile)
Mar-04-21 08:00AM	Portage Biotech Divests Portage Pharmaceuticals Limited to Juvenescence Ltd (Newsfile) -17.86%
Mar-02-21 08:00AM	Portage Announces Filing of Third Quarter Financial Statements (Newsfile) +5.98%

Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Allan L. Shaw	Affiliate	Oct 03 '24	Proposed Sale	5.39	882	4,754	Oct 03 09:18 PM
Allan L. Shaw	Affiliate	Sep 27 '24	Proposed Sale	7.17	10,761	77,156	Sep 27 04:28 PM
Steven Mintz	Director	Sep 18 '24	Proposed Sale	15.96	6,545	104,457	Sep 23 09:41 AM
Gregory Bailey	Director	Sep 18 '24	Proposed Sale	17.65	70,000	1,235,719	Sep 20 11:25 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRTG

Portage Biotech Inc

Upgrade your FINVIZ experience